ADVERTISEMENT
Molecular Classification With Modified ProMisE Algorithm Predicts Survival Outcomes Among Patients With Endometrial Cancer
Aine Clements, MD, Ohio Health, Columbus, Ohio, discussed ancillary results from the phase 3 GOG-0258 trial, as presented at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting.
Results from this ancillary analysis demonstrated that molecular classification based on a modified ProMisE algorithm is prognostic in endometrial cancer and patients with p53-abnormal tumors experience worse overall survival results.
Source:
Clements AE, Enserro D, Strickland KC, et al. Overall survival in patients in GOG-0258 by molecular classification with a modified ProMisE algorithm: Ancillary analysis of GOG-0258. Presented at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting; March 16-18, 2024. San Diego, California